Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
| ▸ | ELANE | P08246 | 2/20 | 0.31 |
| ▸ | CTSG | P08311 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8132766 | 0.82 | ELANE (0.36) | MEN1ALDH1A1KMT2AOPRK1FAAH | |
| SCHEMBL30911200 | 0.80 | FAAH (0.36) | FAAHELANECTSG | |
| SCHEMBL25765744 | 0.79 | ATM (0.38) | MEN1ALDH1A1KMT2A | |
| SCHEMBL25759340 | 0.77 | ELANE (0.55) | ELANECTSG | |
| SCHEMBL25764940 | 0.75 | MEN1 (0.34) | MEN1ALDH1A1KMT2A | |
| SCHEMBL8404674 | 0.73 | MEN1 (0.33) | MEN1ALDH1A1KMT2A | |
| SCHEMBL12924902 | 0.73 | MEN1 (0.33) | MEN1ALDH1A1KMT2A | |
| SCHEMBL5747840 | 0.72 | PSEN1 (0.44) | ALDH1A1KMT2AOPRK1 | |
| Hydrochloric Acid SCHEMBL6998893 | 0.71 | PSEN1 (0.43) | ALDH1A1KMT2AOPRK1 | |
| SCHEMBL3420510 | 0.70 | LMNA (0.31) | ALDH1A1KMT2AOPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1136475-B1 | Piperidine and piperazine compounds for use in the treatment of Alzheimer | HOFFMANN LA ROCHE (CH) | 2004-08-18 | — | — | EP | claimed |
| US-6605723-B2 | Reacting a protected amino acid ester with a 4-substituted butyric acid derivative, cyclizing the protected intermediate, benzylating and decarboxylating the intermediate, asymmetric hydrogenation using a catalyst | HOFFMAN-LA ROCHE INC. | 2003-08-12 | — | — | US | claimed |
| US-20010037026-A1 | Process for the preparation of ethanesul fonyl-piperidine derivatives | EVOTEC INTERNATIONAL GMBH (DE) | 2001-11-01 | — | — | US | claimed |
| US-6605723-B2 | Reacting a protected amino acid ester with a 4-substituted butyric acid derivative, cyclizing the protected intermediate, benzylating and decarboxylating the intermediate, asymmetric hydrogenation using a catalyst | HOFFMAN-LA ROCHE INC. | 2003-08-12 | — | — | US | disclosed |
| US-20010037026-A1 | Process for the preparation of ethanesul fonyl-piperidine derivatives | EVOTEC INTERNATIONAL GMBH (DE) | 2001-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010037026-A1 | Process for the preparation of ethanesul fonyl-piperidine derivatives | GRIN1, GRIN3A, GRIN2B | MEN1 852/4885ALDH1A1 1434/4885KMT2A 2102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.